DSM Biomedical to be Key Contributor at the Surfaces in Biomaterials Foundation's 2010 BioInterface Symposium and Workshop
10/8/2010 7:26:17 AM
BERKELEY, Calif., Oct. 7 /PRNewswire/ --DSM Biomedical, a global leader in biomedical materials science, and its Berkeley based operation, DSM PTG, today announced the Company will be participating at the Surfaces in Biomaterials Foundation's 2010 BioInterface Symposium and Workshop, which will be held October 18 20 in Atlanta, Georgia.
With extensive experience in developing biomaterials for medical devices, the experts at DSM Biomedical will be discussing the latest industry developments. During an October 18th presentation, Jens Thies, Ph.D., business development manager and principal scientist at DSM Biomedical, will present his paper titled "DSM Non-Biofouling Coatings: A Stealth Approach to Fighting Biofilms", which explains how DSM has developed and marketed a variety of hydrophilic UV curable coatings. Further, CEO and president of DSM PTG, Bob Ward, will also discuss exciting applications under contract development by DSM that use biomaterials in a new role, specifically the treatment and prevention of infectious diseases.
"All of us at DSM are honored to be part of a prominent event that brings together world-class experts to discuss advances in the biomaterials industry," said Christophe Dardel, president of DSM Biomedical. "We have an extremely impressive line-up of speakers, all of whom bring their unique expertise and valuable insight to creating innovative solutions for material design and selection, synthesis and characterization, prototype fabrication and manufacturing of components and medical devices. This year's symposium and workshop promises to be exceptional."
Other experts from DSM who will be participating in the symposium and workshop include: Aylvin Dias, Principal Scientist, who is on the 2010 Program Committee and will be chairing the session titled, "Prevention of Biofilm Infections" on October 18, and Alessio Piermattei, Research Scientist, who will present a poster on October 19 on the use of antimicrobial coatings for Central Venous Catheters and prevention of biofilm infections.
To learn more about DSM Biomedical's participation at the event, or to register to attend the conference, go to http://www.surfaces.org/cde.cfm?event=292411.
About DSM Biomedical
DSM Biomedical develops novel materials-based solutions to meet the present and future needs of the medical device and biopharmaceutical industries. Building on the expertise and strengths of DSM and its acquisition of The Polymer Technology Group, which is now known as DSM PTG, the company's product portfolio includes coatings, drug delivery platforms and a wide range of biomedical materials for use in short- and long-term implantable medical devices. Key product brands include Bionate® PCU and CarboSil® TSPCU, two of the most extensively tested biomedical polymers ever developed. Both polymers have excellent biostability, high strength and abrasion resistance, making them candidate materials for load-bearing orthopedic implants. ComfortCoat® hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems; and Dyneema Purity®, a high-performance polyethylene fiber technology developed specifically for use in medical applications, such as orthopedic implants. The company also markets the Trancerta family of bioresorbable materials for drug delivery. This portfolio is based on DSM's core strengths in materials science combined with its extensive in-house library of synthesis methods, formulation and processing techniques. For more information, visit www.dsmbiomedical.com.
DSM the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about 8 billion euro and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.
SOURCE DSM Biomedical